FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Drug Outsourcing Group/FDA Settle Law Suit

[ Price : $8.95]

The Outsourcing Facilities Association and FDA reach a settlement agreement that compels the agency to promptly review long-pendin...

Marked Change Seen in FDA Final CDS Guidance

[ Price : $8.95]

Hyman, Phelps & McNamara attorneys and a medical device regulatory expert say an FDA final guidance on clinical decision support s...

More Quality Issues at Lilly Plant: Reuters

[ Price : $8.95]

Reuters reports that FDA has again found quality issues at the Lilly Branchburg, NJ, drug manufacturing facility.

Priority Review for Gilead Trodelv sBLA

[ Price : $8.95]

FDA accepts for priority review a Gilead Sciences supplemental BLA for Trodelv (sacituzumab govitecan-hziy) for treating certain a...

CGMP Violations at Mexicos Eksa Mills

[ Price : $8.95]

FDA warns Mexicos Eksa Mills about CGMP violations in its manufacturing of finished drugs.

EUA Revoked For Covid-19 Test

[ Price : $8.95]

Federal Register: FDA revokes an emergency use authorization issued to Laboratorio Clinico Toledo, Puerto Rico, for its Laboratori...

Dupixent Filing for Eosinophilic Esophagitis Next Year

[ Price : $8.95]

Regeneron Pharmaceuticals and Sanofi say they will seek FDA approval next year for Dupixent (dupilumab) and its use in treating ch...

Draft Guide on ANDA Facility Inspection Readiness

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Facility Readiness: Goal Date Decisions Under GDUFA.

FDA Rejects Supernus NDA for Parkinsons Drug

[ Price : $8.95]

FDA sends Supernus Pharmaceuticals a complete response letter on its NDA for SPN-830 (apomorphine) infusion device for the continu...

Data Backs Pulmonary Hypertension Drug: Merck

[ Price : $8.95]

Merck reports positive top-line results from a pivotal Phase 3 trial (STELLAR) evaluating the safety and efficacy of sotatercept, ...